Navigation Links
Docetaxel May Boost Outcomes For Breast Cancers That Haven't Spread to Lymph
Date:12/1/2010

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Dec. 1 (HealthDay News) -- A chemotherapy regimen already proven superior to other regimens for breast cancer that has spread to the lymph nodes may also work better for some women whose cancers haven't spread, a new study has found.

When it came to these "node-negative" cancers, the drug combination of docetaxel, doxorubicin and cyclophosphamide (dubbed TAC) outperformed the combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC), the Spanish study authors said.

The TAC regimen was better at keeping women alive and disease-free after a median follow up of almost six and a half years, the study found.

''For those women with higher-risk, node-negative breast cancer, in which chemotherapy is indicated, TAC is one of the most interesting options," said study co-author Dr. Miguel Martin, a professor of medical oncology at the Hospital General Universitario Gregorio Maranon in Madrid.

The study was funded by the drug maker Sanofi-Aventis -- which makes Taxotere, the brand name for docetaxel -- and GEICAM, the Spanish Breast Cancer Research Group. The results are published in the Dec. 2 issue of the New England Journal of Medicine.

To determine which women with breast cancer would benefit from adjuvant chemotherapy (typically chemotherapy after surgery), doctors take into account a number of risk factors, such as the patient's age, tumor size and other characteristics.

For the new study, the researchers assigned 1,060 women with breast cancers that were axillary-node negative who had at least one high-risk factor for recurrence to one of the two treatment regimens every three weeks for six cycles after their surgery.

At the 77-month mark, almost 88 percent of the TAC women were alive and disease-free, compared to close to 82 percent of the women in the FAC group. Those in the TAC group had a 32 percent reduction in the risk of recurrence, the study authors said.

The reduced risk held true even after taking into account a number of high-risk factors, such as age, the women's menopausal status and tumor characteristics.

The differences in survival rates weren't significant from a statistical point of view -- 95.2 percent of TAC-treated women survived the follow-up, compared to 93.5 percent of the FAC-treated women.

However, adverse events from the drugs were more common with TAC -- 28 percent of patients, compared to 17 percent of the FAC patients.

''TAC is more toxic," Martin said, adding that ''all the toxicities were reversible." One common side effect was neutropenia, an abnormally low number of white blood cells. Fatigue was also a problem, the study found.

Another consideration: TAC chemotherapy is also substantially more expensive than FAC, Martin said, although he could not specify exactly how much more.

Even so, he said, "I think this study provides grounds for thinking of this regimen, particularly for those women with high-risk node-negative breast cancers."

Dr. Minetta Liu, director of translational breast cancer research at the Lombardi Comprehensive Cancer Center at Georgetown University, said the new study supports what many oncologists are already doing.

"Many oncologists are incorporating taxenes [such as docetaxel] in the adjuvant treatment for node-negative breast cancer," said Liu, who reviewed the study findings but was not involved with the research.

The ongoing challenge, Liu said, is deciding which women need the additional therapy. "This particular study's importance is that it illustrates there is a benefit in incorporating a taxene into the adjuvant treatment for some women with node-negative breast cancer."

More information

To learn more about breast cancer treatment, visit the U.S. National Cancer Institute.

SOURCES: Miguel Martin, M.D., Ph.D., professor of medical oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain; Minetta Liu, M.D., director of translational research, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.; New England Journal of Medicine, Dec. 2, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
2. New lung disease network to benefit patients and boost UK economy
3. Love Hormone May Boost Mens Memories of Mom -- Good or Bad
4. Love Hormone Boosts Memories of Mom -- Good or Bad, Study Finds
5. Behavior Disorders Boost Crash Risk for Teen Boys: Study
6. Poor Children Get Biggest Literacy Boost From Preschool
7. Higher Plavix Dose Wont Boost Outcomes After Stent Placement: Study
8. Scientists Find Way to Boost Good Cholesterol in Mice
9. Setting National Hospital Standards Could Boost Cardiac Care
10. Small assist device used in emergency case as twin, heart booster pumps for first time in US
11. Math Skills Boost Couples Financial Worth: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist , ... office, Antoine Dental Center. Currently, patients can get single dental implants for $3,599 ... patients can learn more about these offers by contacting Antoine Dental Center. Both ...
(Date:2/24/2017)... ... ... An in-depth computational analysis of genetic variants implicated in both schizophrenia and rheumatoid ... explain why susceptibility to one of the disorders could place individuals at lower risk ... journal npj Schizophrenia. , “There is a wealth of genomic data on both ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec ... it’s not if you will be attacked, but when.” However, he and many others ... health care. , Improvements in auditing and monitoring have taken security in health care ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 ITL Limited, ( ASX: ITD ), ... for the half year ended 31 December 2016 compared with the ... presentation can be viewed here . Highlights ... $1.04m; up 104%) Earnings per share of 2.2 ... of $17.5m (Dec 2015: $15.7m; up 11%) Profit ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... 23, 2017 Obese people are ... for varicose veins in their body. The rising number ... the adoption of endovenous laser therapy for treatment of ... laser therapy market, published by Future Market Insights, ... and consequences of obesity have collectively factored the growth ...
Breaking Medicine Technology: